Clearmind Medicine (Nasdaq: CMND) reports improved nasal MEAI retention
Rhea-AI Filing Summary
Clearmind Medicine Inc., a clinical-stage biotechnology company focused on non-hallucinogenic neuroplastogen-derived treatments for alcohol use disorder, addiction and weight management, reported ex vivo mucoadhesion data showing its intranasal MEAI formulation maintained greater nasal tissue retention than a standard MEAI solution over a 30-minute evaluation.
The company explains that enhanced nasal residence is important because longer contact with nasal mucosa can increase absorption and therapeutic potential, supporting its intranasal MEAI program aimed at overcoming rapid mucociliary clearance. Clearmind also highlights a portfolio of nineteen patent families, including 32 granted patents, underpinning its neuroplastogen platform.
Positive
- None.
Negative
- None.
Filing Explained
The July 16 6-K updates registration-statement disclosure but reports no new share issuance, offering, proceeds, or note conversion.
As a Form 6-K, the July 16 filing furnishes interim information published by the foreign private issuer; it incorporates the first eight paragraphs of its press release into specified Form F-3 and Form S-8 registration statements from the filing date. The disclosure update does not state that shares were offered, sold, issued, or converted.
The supplied shelf record shows an effective F-3 dated
Key Figures
Key Terms
mucoadhesion medical
neuroplastogen medical
mucociliary clearance medical
intranasal drug administration medical
mucoadhesive polymer system medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Clearmind Medicine (CMND) disclose in the July 2026 Form 6-K?
How could improved nasal retention of MEAI benefit Clearmind Medicine (CMND)?
What is MEAI and which conditions is Clearmind Medicine (CMND) targeting?
What development stage and intellectual property position does Clearmind Medicine (CMND) report?
How does the intranasal MEAI study relate to Clearmind Medicine’s (CMND) drug-delivery platform?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: July 2026
Commission file number: 001-41557
CLEARMIND MEDICINE INC.
(Translation of registrant’s name into English)
101 – 1220 West 6th Avenue
Vancouver, British Columbia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
CONTENTS
Attached hereto and incorporated herein is the Registrant’s press release issued on July 16, 2026, titled “Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI”.
The first eight paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293, 333-290404, 333-293521 and 333-295455) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
1
EXHIBIT INDEX
| Exhibit No. | ||
| 99.1 | Press release titled: “Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI” |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Clearmind Medicine, Inc. | ||
| (Registrant) | ||
| Date: July 16, 2026 | By: | /s/ Adi Zuloff-Shani |
| Name: | Adi Zuloff-Shani | |
| Title: | Chief Executive Officer | |
3
Exhibit 99.1
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
Vancouver, Canada, July 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering non-hallucinogenic neuroplastogen-derived treatments for Alcohol Use Disorder (AUD), addiction, and weight management, announced today compelling ex vivo mucoadhesion results for its intranasal formulation of MEAI (5-Methoxy-2-aminoindane). Leveraging a nasal drug-delivery system, the new formulation demonstrated markedly improved nasal residence characteristics compared with a standard MEAI solution.
Enhanced nasal retention is a critical step toward maximizing MEAI absorption and therapeutic potential. These results reinforce Clearmind’s strategy of developing differentiated, next-generation treatments for AUD and other high-need indications.
The study forms a core component of Clearmind’s intranasal MEAI development program, designed to overcome the limitations of rapid mucociliary clearance and deliver more consistent, effective dosing.
The study was conducted as part of Clearmind’s development program focused on the development of an intranasal formulation of MEAI for the treatment of AUD. A key objective of the program is to improve the residence time of MEAI within the nasal cavity, potentially increasing the opportunity for absorption before mucociliary clearance removes the formulation from the nasal surface.
Ex Vivo Nasal Residence Time Evaluation
The ex vivo mucoadhesion study was designed to evaluate the ability of its intranasal MEAI formulation to remain associated with nasal tissue over time compared with a non-mucoadhesive MEAI solution. Using freshly isolated rabbit nasal mucosa, both formulations were applied to the tissue surface and allowed to interact with the mucosa before exposure to a simulated nasal electrolyte solution. The amount of formulation retained on the tissue was measured over a 30-minute period to generate comparative residence time profiles.
The intranasal MEAI formulation consistently maintained a greater proportion of its initially adhered dose throughout the entire evaluation period, demonstrating a clear retention advantage over the reference solution.
These results highlight the contribution of the mucoadhesive polymer system incorporated into the intranasal MEAI formulation and provide further validation of Clearmind’s nasal drug-delivery platform, which is engineered to increase formulation residence at mucosal surfaces and enhance overall delivery performance.
Extended residence time within the nasal cavity is widely recognized as a key factor in effective intranasal drug administration, as prolonged contact with the nasal mucosa increases the opportunity for absorption and may improve therapeutic efficiency. The observed retention profile suggests that Clearmind’s intranasal MEAI formulation may offer meaningful advantages over conventional non-mucoadhesive approaches.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential of MEAI, the ability to improve the residence time of MEAI within the nasal cavity, potentially increasing the opportunity for absorption, the company’s intention to seek additional patents for its compounds whenever warranted and that it will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.